Stempoint Capital’s Keros Therapeutics KROS Stock Holding History

Stempoint Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-86,930	Closed	-$5.05M	–	69
2024 Q3	$5.05M	Buy	+86,930	New	+$4.29M	1.51%	20

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Stempoint Capital's KROS Position: Q4 2024 in Review

Stempoint Capital sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 86,930 shares — an estimated $5.05M sold.

Stempoint Capital first reported a position in KROS in Q3 2024 and held it in 1 quarter. The position peaked at $5.05M in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

Stempoint Capital reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
Stempoint Capital sold 86,930 Keros Therapeutics shares in Q4 2024, an estimated $5.05M.
Stempoint Capital first reported a position in Keros Therapeutics in Q3 2024 and held it in 1 quarter.
Stempoint Capital's Keros Therapeutics position peaked at $5.05M in Q3 2024.
161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.